155 related articles for article (PubMed ID: 1647898)
1. Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up.
Tsagarakis S; Grossman A; Plowman PN; Jones AE; Touzel R; Rees LH; Wass JA; Besser GM
Clin Endocrinol (Oxf); 1991 May; 34(5):399-406. PubMed ID: 1647898
[TBL] [Abstract][Full Text] [Related]
2. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
Sibal L; Ugwu P; Kendall-Taylor P; Ball SG; James RA; Pearce SH; Hall K; Quinton R
Pituitary; 2002; 5(4):243-6. PubMed ID: 14558672
[TBL] [Abstract][Full Text] [Related]
3. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
4. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
5. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
6. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas.
Arafah BM
J Clin Endocrinol Metab; 1986 Jun; 62(6):1173-9. PubMed ID: 3009521
[TBL] [Abstract][Full Text] [Related]
7. Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients.
Rubio MA; Cabranes JA; Schally AV; Charro AL
J Clin Endocrinol Metab; 1989 Aug; 69(2):444-7. PubMed ID: 2526819
[TBL] [Abstract][Full Text] [Related]
8. Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests.
Webster J; Page MD; Bevan JS; Richards SH; Douglas-Jones AG; Scanlon MF
Clin Endocrinol (Oxf); 1992 Jan; 36(1):35-44. PubMed ID: 1559298
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
[TBL] [Abstract][Full Text] [Related]
10. The effect of external pituitary irradiation on elevated serum prolactin levels in patients with pituitary macroadenomas.
Littley MD; Shalet SM; Reid H; Beardwell CG; Sutton ML
Q J Med; 1991 Dec; 81(296):985-98. PubMed ID: 1808643
[TBL] [Abstract][Full Text] [Related]
11. Changes in pituitary hormones during and following transsphenoidal removal of prolactinomas.
Casper RF; Rakoff JS; Quigley ME; Gilliland B; Alksne J; Yen SS
Am J Obstet Gynecol; 1980 Feb; 136(4):518-23. PubMed ID: 6766667
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
[TBL] [Abstract][Full Text] [Related]
13. Impaired growth hormone secretion in patients operated for pituitary adenomas.
Hoeck HC; Bang F; Laurberg P
Growth Regul; 1994 Jun; 4(2):63-7. PubMed ID: 7950904
[TBL] [Abstract][Full Text] [Related]
14. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
Barnett PS; Palazidou E; Miell JP; Coskeran PB; Butler J; Dawson JM; Maccabe J; McGregor AM
Q J Med; 1991 Nov; 81(295):891-906. PubMed ID: 1687293
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of allogeneic bone marrow transplantation (BMT) on pituitary, gonad, thyroid and adrenal function in adults.
Kauppila M; Koskinen P; Irjala K; Remes K; Viikari J
Bone Marrow Transplant; 1998 Aug; 22(4):331-7. PubMed ID: 9722067
[TBL] [Abstract][Full Text] [Related]
16. Partial hypopituitarism and hyperprolactinemia: successful induction of ovulation with bromocriptine and human menopausal gonadotropins.
Dawood MY; Jarrett JC; Choe JK
Fertil Steril; 1982 Oct; 38(4):415-8. PubMed ID: 6811337
[TBL] [Abstract][Full Text] [Related]
17. Serum prolactin in patients with "functionless" chromophobe adenomas before and after therapy.
Samaan NA; Leavens ME; Jesse JH
Acta Endocrinol (Copenh); 1977 Mar; 84(3):449-60. PubMed ID: 402758
[TBL] [Abstract][Full Text] [Related]
18. Pituitary stimulation by combined administration of four hypothalamic releasing hormones in normal men and patients.
Cohen R; Bouquier D; Biot-Laporte S; Vermeulen E; Claustrat B; Cherpin MH; Cabrera P; Guidetti P; Ferry S; Bizollon CA
J Clin Endocrinol Metab; 1986 May; 62(5):892-8. PubMed ID: 3007559
[TBL] [Abstract][Full Text] [Related]
19. Megavoltage pituitary irradiation in the management of Cushing's disease and Nelson's syndrome: long-term follow-up.
Howlett TA; Plowman PN; Wass JA; Rees LH; Jones AE; Besser GM
Clin Endocrinol (Oxf); 1989 Sep; 31(3):309-23. PubMed ID: 2559823
[TBL] [Abstract][Full Text] [Related]
20. The long-term effects of megavoltage radiotherapy as sole or combined therapy for large prolactinomas: studies with high definition computerized tomography.
Johnston DG; Hall K; Kendall-Taylor P; Ross WM; Crombie AL; Cook DB; Watson MJ
Clin Endocrinol (Oxf); 1986 Jun; 24(6):675-85. PubMed ID: 3098457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
